Pfizer's Financial Outlook: Modest Growth Amidst Challenges
Update: 2025-12-16
Description
Pfizer anticipates modest growth in 2026, despite declining COVID product sales and increased competition for older drugs. The company is investing in new revenue streams following pandemic-driven sales records. Recent acquisitions, such as Metsera and Seagen, are expected to contribute to the bottom line in the future. Pfizers adjusted profit forecast for 2026 is slightly below expectations, with revenue projected to remain flat. Patent expirations and lower Eliquis prices in Medicare will impact revenue. Despite these challenges, Pfizer has cut costs and remains committed to vaccine investments, undeterred by policy uncertainty.
The Daily News Now! — Every city. Every story. AI-powered.
Hosted on Acast. See acast.com/privacy for more information.
Comments
In Channel
Download from Google Play
Download from App Store
United States00:00
00:00
1.0x
